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ABSTRACT
Autologous stem cell transplantation (ASCT) is the standard of care for patients with multiple myeloma (MM)
younger than 70 years.However, despite this aggressive therapymost patients will still die of progressive disease.
Recent reports have suggested that lymphocyte recovery is an important predictor of relapse or progressive dis-
ease in a number of hematologicmalignancies includingMM.Wehave conducted retrospective analysis of factors
that could predict overall (OS) and progression free survival (PFS) in patientswithMMwhohadASCT.Onehun-
dred nineteen patients with multiple myeloma underwent ASCT. The median OS and PFS were 64 and 32
months, respectively. Univariate and multivariate analysis using Cox proportional hazards regression model
showed that absolute lymphocyte count on day 30 following ASCT (ALC-30), international staging system
(ISS) stage at diagnosis, and age at diagnosis significantly influenced OS and PFS following ASCT. OS (96 versus
48months,P5 .04) andPFS (43 versus 29months,P5 .03) followingASCTwere higher in patients withALC-30
$1.0  109/L compared to patients ALC-30\1.0  109/L. Higher ALC-60, ALC-100, ALC-180, and ALC-365
did not predict superiorOS andPFS.Patientswith early-stage disease had significantly higherOS (ISS stages I, II,
and III: 96, 53, and 29months, respectively; P5 .0023) and PFS (ISS stages I, II, and III: 55.5, 31, and 12months,
respectively; P5 .027) compared to patients with advanced-stage disease at diagnosis. On univariate analysis, the
type of initial chemotherapy (melphalan, VAD, PCAB), lymphocyte count on day of leukapheresis, and the
lymphocyte dose infused (LY-DO) significantly influenced lymphocyte recovery following ASCT. Patients who
received higher lymphocyte dose (LY-DO)$0.2  109/kg had higher median ALC-15 (0.25 versus 0.19  109/L;
P 5 .3), ALC-30 (1.20 versus 0.99  109/L; P 5 .08), ALC-60 (1.90 versus 1.01  109/L; P 5 .013) , ALC-100
(1.58 versus 1.03109/L;P5 .016), andALC-180 (1.33 versus 1.01109/L;P5 .1), compared topatientswho re-
ceivedLY-DO\0.2109/kg. In summary, our data suggest that infusing largenumbers of lymphocytes improves
lymphocyte recovery post-ASCT, and that higher ALC-30 is associated with better PFS andOS. These data sug-
gest that a threshold number of CD341 cells should not be the only parameter considered for an adequate
PBSC collection—perhaps a certain number of lymphocytes should be aimed for as well.
 2008 American Society for Blood and Marrow Transplantation
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Autologous stem cell transplant (ASCT) improves
survival of multiple myeloma (MM) patients [1], al-
though the vast majority of patients are still destined116to relapse. Progressive disease following ASCT is
largely attributed to the inability of conditioning che-
motherapy to eliminate all the malignant cells. In allo-
geneic SCT residual disease is eradicated or controlled
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cytes, which appear to be lacking in ASCT. Early
lymphocyte recovery following allogeneic SCT is
associated with improved overall survival (OS) and
disease-free survival [2]. The concept of GVT was
further strengthened by donor lymphocyte infusion
(DLI) inducing remission in patients who relapsed fol-
lowing allogeneic SCT [3-5]. This GVT effect of DLI
was further harnessed in nonmyeloablative allogeneic
SCT.
During the last decade, there has been increased
interest in immune reconstitution following ASCT
and its effect on OS and progression free survival
(PFS). Absolute lymphocyte count recovery at day 15
(ALC-15) after ASCT has been reported as a powerful,
independent prognostic indicator of clinical outcomes
for patients with acute myelogenous leukemia (AML)
[6], breast cancer [7], Hodgkin lymphoma [8,9] non-
Hodgkin lymphoma (NHL) [10-15], and primary sys-
temic amyloidosis [16] with improvements in PFS and
OS. There is limited literature correlating lymphocyte
recovery and survival following ASCT in MM [14,17].
None of these studies addressed the influence of
lymphocyte recovery over various time points on
survival following ASCT. Here we have conducted
retrospective analysis of factors that could predict
OS and PFS following ASCT. We have also analyzed




Between January 1992 and December 2004, 119
patients with MM underwent ASCT. There were 76
male and 43 female patients, and their median age
was 57 (30-70) years. At diagnosis most of the patients
(n 5 96) had been treated with single chemotherapy
regimen, whereas other patients (n 5 23) had been
treated with multiple chemotherapy regimens (Table
1). Peripheral blood stem cells (PBSCs) were collected
following low dose cyclophosphamide and granulo-
cyte colony-stimulating factors (G-CSF; LD-CY 1 to
2 g/m2 ; n5 55), intermediate dose cyclophosphamide
and G-CSF (ID-CY 3 to 4 gm/m2 ; n 5 44), or other
mobilization chemotherapy (n5 20). All patients pro-
vided written informed consent for ASCT. Following
ASCT, response to therapy was updated until June
2005.
ASCT conditioning chemotherapy. All patients
received melphalan-based conditioning chemother-
apy, most commonly melphalan 200 mg/m2 (n 5
100). Some patients received melphalan (140 mg/m2)
plus busulfan (16 mg/kg) (n 5 12), melphalan (140
mg/m2) and total body irradiation (TBI) (n 5 4), or
melphalan (100 mg/m2) (n5 3). Following condition-
ing chemotherapy, 117 patients received PBSC trans-plant, and 2 patients had PBSCs and bone marrow
stem cells. Posttransplant G-CSF was started on
D 11 in 47 patients as a part of a clinical trial.
Engraftment
Engraftment was defined as first of 3 consecutive
days to neutrophil$0.5  109/L and first of 7 consec-
utive days to platelet $20 1 09/L without platelet
transfusion.
Response and survival. Response was defined as
per EBMTR/IBMTR/ABMTR criteria [18].
Table 1. Disease Characteristics of Patients
Variables Median (Range)
Total number of patients (n) 119
Median (range) age (years) 57 (30-70)
Sex M/F 76/43








Lambda light chain disease 10






Median (range) albumin (g/L) 36 (12-48)
Median (range) b2-M at diagnosis (mg/L) 3.05 (0.20-34.1)
Median (range) CRP at diagnosis (mg/L) 3 (1-119)
Absolute lymphocyte count at diagnosis
(109/L) median (range)
1.61 (0.26-4)
LDH at diagnosis U/L, median (range) 193 (61-646)
Number of patients received single line of
chemotherapy prior to stem cell
collection
96
VAD combination chemotherapy 41
CID combination chemotherapy 35
PCAB combination chemotherapy 13
Melphalan and prednisolone 7
Number of patients received $2 type of
chemotherapy regimens prior to stem
cell collection
23
PCAB 1 other combination
chemotherapy (VAD/CID)
9




Duration of prior treatment (months) 5 (2-45)
Number of patients received
radiotherapy
41
CRP indicates C-reactive protein; PCAB, prednisone, cyclophos-
phamide, adriamycin, BCNU; ISS, International staging system;
b2-M: beta-2 microglobulin; VAD, vincristine, adriamycin, and
dexamethasone; CID, cyclophosphamide, idarubicin, and dexa-
methasone; DT-PACE: Dexamethasone, thalidomide, predniso-
lone, adriamycin, cyclophosphamide, etoposide; LDH, lactate
dehydrogenase.
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In addition to absolute lymphocyte count (ALC)
recovery following ASCT, other factors that may in-
fluence OS and PFS were analyzed by univariate and
multivariate analysis. These factors included age, b2-
microglobulin, albumin, international staging system
(ISS), C-reactive protein, lactate dehydrogenase,
bone marrow plasma cell percentage at diagnosis,
number of pretransplant chemotherapy courses, dis-
ease status prior to ASCT, engraftment kinetics, and
response following ASCT were analyzed. Cytogenetic
analysis was not available on most patients, and hence
was not able to be included in the analysis. ALC on day
115 (ALC-15), day 130 (ALC-30), day 160 (ALC-
60), day 1100 (ALC-100), day 1180 (ALC-180), and
day 1365 (ALC-365) were obtained from peripheral
blood counts at respective time points following
ASCT.
Various factors that could potentially influence
lymphocyte recovery following ASCT were also ana-
lyzed. These factors include lymphocyte dose infused
(LY-DO), CD341 cell dose infused, chemotherapy
prior to ASCT, conditioning chemotherapy, post-
transplant G-CSF, lymphocyte count at diagnosis, as
well as on day of leukapheresis and prior to ASCT.
LY-DO was calculated as (total nucleated cells infused
% of lymphocyte). Total cell count and percentage
of lymphocyte were assessed by automatic cell counter.
Statistical Analysis
Analysis was performed using SAS version 8.2
(SAS Institute Inc., Cary, NC).
All outcome variables were initially assessed for
normality and log-transformed where appropriate.
Group comparisons were performed using chi-square
tests for equal proportion, Student t-tests, or Wil-
coxon rank sum tests where distributions were non-
parametric. Univariate and multivariate analysis of
factors that could influence OS and PFS were per-
formed using Cox proportional hazards regression
model. Survival was presented using Kaplan-Meier
curves, and significance was analyzed by using log
rank tests. To determine longitudinal relationships,
generalized linear modeling adjusting for repeat mea-
sures was used. A 2-sided P-value of .05 was considered
to be statistically significant.
OS time was measured from date of transplanta-
tion to the date of death or last follow-up. PFS was
defined as time from transplantation to disease pro-
gression, relapse, or death.
Patients were subcategorized according to median
ALC, and OS and PFS survival were compared. The
median ALC-15 was 0.2  109/L, and hence the pa-
tients were subcategorized into 2 groups (ALC-15
$0.2  109/L and\0.2  109/L).The median ALC-
30, ALC-60, ALC-100, ALC-180, ALC-365, was1  109/L, and hence patients were subdivided into 2
groups ALC $1.0  109/L and\1.0  109/L.
RESULTS
Demographics
The study cohort consists of 119 consecutive pa-
tients with MM who underwent ASCT (Table 1).
The median number of CD341 cell infused was 3.95
(1.3 to 33.7)  106/kg. None of the patients received
purged or CD341 cell-selected PBSCs. Nine patients
died prior to engraftment. The engraftment and lym-
phocyte recovery data of the remaining 110 patients
are shown in Table 2.
Outcome
Following ASCT, 32 (27%) patients achieved
complete remission, 76 (64%) patients achieved partial
remission, 1 patient had stable disease, and 9 patients
died prior to engraftment. Response to ASCT could
not be assessed in 1 patient because of inadequate data.
At the time of analysis, 74 (62%) were alive and 45
(38%) patients were deceased. Nine (8%) patients died
within 100 days of ASCT (8 deaths were because of
septicemia and 1 was because of intracranial hemor-
rhage) and 36 (30%) patients died of progressive dis-
ease. The median OS of all patients was 64 months
and PFS was 32 months. At last follow-up, 22, 37,
and 15 patients, respectively, were in CR, PR, or had
progressive disease. The OSs according to ISS stages
I, II, and III at diagnosis were 96, 53, and 29 months,
respectively (P 5 .0023) and PFSs were 96, 32, and
11 months (P\ .0001), respectively.
Factors Influencing OS and PFS
Univariate analysis. On univariate analysis ALC-
30, age, ISS stage, disease status prior to ASCT, and
response to ASCT (Table 3) significantly influenced
OS and PFS.
There was no significant correlation between
ALC-15 (P 5 .25), ALC-60 (P 5 .99), ALC-100




Days to neutrophil .0.5  109/L 15 (10-53)
Days to platelet .20  109/L) 19 (9-119)
ALC-15 0.19 (0-2.54)  109/L
ALC-30 1.0 (0.06-5.59)  109/L
ALC-60 1.29 (0.05-6.570)  109/L
ALC-100 1.13 (0.2-7.3)  109/L
ALC- 180 1.07 (0.2-3.32)  109/L
ALC-365 1.19 (0.30-3.47)  109/L
ALC indicates absolute lymphocyte count.
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OS PFS
Factors Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Age 1.05 (1.01-1.10) .012 1.04 (1.00 to 1.08) .03
ISS stage at diagnosis 1.10 (1.05-1.16) \.001 1.13 (1.06 to 1.20) .002
Bone marrow plasma cell percentage
at diagnosis
1.02 (1.00-1.03) .001 1.014 (1.002 to 1.03) .029
Platelet count at diagnosis 0.99 (0.98-0.99) .001 0.995 (0.98 to 0.99) .014
Serum calcium at diagnosis 2.16 (1.30 to 3.60) .002 1.950 (1.6 to 6.8) .008
Platelet count prior to mobilization 0.99 (0.98-0.99) \.001 0.996 (0.98 to 0.99) .013
Disease status prior to ASCT 1.87 (1.23-2.84) .003 1.35 (0.89 to 2.05) .15
Platelet count prior to ASCT 0.99 (0.98-0.99) \.001 0.995 (0.98 to 0.99) .002
Response following ASCT 4.69 (2.5-8.21) \.001 2.693 (1.35 to 9.21) \.001
ALC-30 0.57 (0.34-0.95) .028 0.62 (0.55 to 0.92) .030
ASCT indicates autologous stem cell transplantation; ALC, absolute lymphocyte count; CI, confidence interval.(P5 .63), ALC-180 (P5 .66), and ALC-365 (P5 .69)
and either OS or PFS.
Multivariate analysis. On multivariate analysis,
OS and PFS were strongly influenced by ALC-30
(OS: P 5 .008, hazzard ratio [HR] 5 0.44; PFS:
P 5 .04, HR 5 0.43). Patients with ALC-30 $1.0 
109/L had significantly higher PFS (P5 .03) compared
to patients with ALC-30\1.0  109/L. Other factors
that significantly influenced OS and PFS were ISS
stage at diagnosis (OS: P\ .001, HR 5 1.12; PFS:
P\ .001, HR 5 1.12), age at diagnosis (OS: P 5 .03,
HR 5 1.06, PFS: P 5 .03, HR 5 1.04), and response
following ASCT (OS: P 5 .001, HR 5 0.06, PFS:
P 5 .003, HR 5 0.04).
Lymphocyte recovery kinetics. Median ALC-30
(0.98  109/L) was significantly higher (P \ .001)
compared to median ALC-15 (0.19  109/L); how-
ever, median ALC-60 (1.29  109/L), ALC-100
(1.13  109/L), ALC-180 (1.07  109/L), and ALC-
365 (1.19  109/L) were not significantly higher than
ALC-30 (P 5 .09). Patients who achieved ALC-30
.1.0  109/L have significantly higher ALC-60,
ALC-100, and ALC-180 compared to patients with
ALC-30\1.0  109/L (Figure 1).
Median ALC-15 was 0.19 109/L, and we catego-
rized patients according to median ALC-15. There
was no significant difference in median OS (P 5 .39)
and PFS (P 5 .56) in patients with ALC-15 $0.2 
109/L (OS 80; PFS 43 months; n 5 59) compared to
patients with ALC-15\0.2  109/L (OS 53, PFS 31
months; n5 60, Table 4). In our study only 21 patients
achieved ALC-15 $0.5  109/L and their median
values for OS and PFS were not reached compared
to 63 and 29 months in patients with ALC-15\0.5
 109/L (n 5 98; OS: P 5 .72, PFS: P 5 .44).
The median ALC-30 was 1.0  109/L (0.06-5.6)
and median OS was significantly higher in patients
with ALC-30 $1.0  109/L (96 months; Figure 2)
compared to patients with ALC-30 \1.0  109/L
(48 months, P 5 .01). Similarly, PFS was also signifi-cantly higher in patients with ALC-30 $1.0  109/L
(43 months) compared to patients with ALC-30\1.0
 109/L (29 months; P 5 .04; Figure 3 and Table 4).
At the time of analysis, 74 (62%) were alive and 45
(38%) patients were deceased. Among patients who
died of progressive disease, the median ALC-30 was
lower (0.76  109/L) compared to the patients who
were alive (1.09  109/L; P 5 .005) at last follow-up.
However, achieving higher ($1.0  109/L) ALC-
60, ALC-100, ALC-180, and ALC-365 were not asso-
ciated with survival benefit (Table 4). These data show
that higher lymphocyte recovery within 30 days of
ASCT is associated with survival benefit; however,
delayed higher lymphocyte recovery did not confer
similar benefit.
Factors Associated with Lymphocyte Recovery
following ASCT
As discussed earlier, higher ALC-30 was associated
with survival benefit. Hence, we analyzed factors that
could potentially influence lymphocyte recovery
following ASCT. On univariate analysis LY-DO
(P 5 .04), PCAB (P 5 .01), and melphalan (P 5 .05)
Figure 1.Compares lymphocyte recovery according to ALC-30: pa-
tients who achieved ALC-30 $1.0  109/L have higher ALC-60,
ALC-100, ALC-180, and ALC-365 compared to patients with
ALC-30\1.0  109/L.
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365
ALC (109/L) Number of Patients OS Median (95% CI) Months P PFS Median (95% CI) Months P
ALC-15\0.2 59 53 (37 to 66) .39 31 (25-37) .56
ALC-15 $0.2 60 80 (20 to 114) 43 (25-61)
ALC-15\0.5 98 63 (42 to 84) .72 31 (25-38) .44
ALC-15 $0.5 21 Not reached Not reached
ALC-30\0.5 24 53 (47-79) .014 31 (17-46) .39
ALC-30 $0.5 87 80 (29-131) 38 (19-46)
ALC-30\1.0 49 53 (27-78) .006 29 (16-42) .03
ALC-30 $ 1.0 58 96 (34-158) 43 (23-48)
ALC-60\1.0 33 72 (58-87) .70 32 (18-45) .95
ALC-60 $1.0 53 80 (39-121) 31 (10-52)
ALC-100\1.0 35 64 (28-92) .75 36 (24-49) .4
ALC-100 $1.0 58 80 (32-128) 29 (12-47)
ALC-180\1.0 40 80 (56-104) .87 43 (28-57) .61
ALC-180 $1.0 54 53 (18-87) 31(24-39)
ALC-365\1 35 82 (59-107) .76 43 (25-60) .74
ALC-365 $1 82 72 (42-103) 36 (27-50)chemotherapy and lymphocyte counts on the first day
of leukapheresis (P 5 .001) influenced ALC recovery.
On multivariate repeated-measures analysis PCAB
(P 5 .027), melphalan (P 5 .024) chemotherapy prior
to ASCT and lymphocyte counts on the first day
leukapheresis (P 5 .0002) were associated with ALC
recovery.
Lymphocyte dose infused. Median LY-DO was
0.09 (0.01 to 0.87) 109/kg. ALC recovery was higher
in patients who received LY-DO$0.09 109/kg com-
pared to LY-DO\0.09 109/kg; however, the differ-
ence between the 2 groups was statistically significant
only for ALC-60 (P5 .007; Table 5). To assess if there
is dose threshold of LY-DO, we categorized patients
by using different cutoffs for LY-DO. Patients who re-
ceived higher LY-DO ($0.2  109/kg) achieved
higher median ALC-15, ALC-30, ALC-60, and
ALC-180 compared to patients who received LY-
DO\0.2  109/kg (Table 5). These 2 groups were
balanced for other factors that influenced ALC recov-
ery following ASCT. Percentage of patients who re-
Figure 2.OS following ASCT is significantly higher in patients with
ALC-30 $1.0  109/L (96.06 months) compared to patients with
ALC-30\1.0  109/L (48.26 months, P 5 .006).ceived melphalan and PCAB chemotherapy prior to
stem cell collection (18% versus 20% and 19% versus
20%, respectively) were similar in the 2 groups. Me-
dian lymphocyte counts on the day of leukapheresis
were similar (1.32  109/L versus 1.34  109/L) in
both groups. We have also observed that there was
a continuous dose-dependent effect of LY-DO on
ALC recovery (Figure 4).
The median OS (P5 .4) and PFS (P5 .7) was not
significantly different in patients who received LY-DO
$0.09  109/kg versus LY-DO \0.0.09  109/kg.
Similarly, we could not demonstrate survival differ-
ence when patients were categorized according to
LY-DO $0.2  109/kg and LY-DO\0.2  109/kg.
CD34 dose infused. There was no correlation be-
tween CD341 stem cell dose infused and lymphocyte
recovery following ASCT. Patients were further di-
vided into 2 groups according median CD341 stem
Figure 3. PFS following ASCT is significantly higher in patients
with ALC-30 $1.0  109/L (43.06 months) compared to patients
with ALC-30\1.0  109/L (28.96 months, P 5 .03).
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LY-DO\0.09  109/kg LY-DO .0.09  109/kg LY-DO\0.2  109/kg LY-DO .0.2  109/kg
ALC Median (Range) Median (Range) P Median (Range) Median (Range) P
ALC-15 0.19 (0.0-1.92) 0.19 (0.0-1.92) .87 0.19 (0.0-1.9) 0.25 (0.0-2.54) .37
ALC-30 1.06 (0.15-2.5) 1.0 (0.15-5.5) .73 0.99 (0.06-2.6) 1.28 (0.39-5.5) .08
ALC-60 0.9 (0.43-6.4) 1.67 (0.05-6.5) .00 1.0 (0.15-6.5) 1.90 (0.05-5.5) .01
ALC-100 1.02 (0.4-3.7) 1.20 (0.24-7.3) .35 1.03 (0.24-5.1) 1.55 (0.59-7.3) .01
ALC-180 1.02 (0.2-3.32) 1.07 (0.24-3.1) .82 1.0 (0.2-3.32) 1.33 (0.63-3.1) .11
ALC-365 1.12 (0.33-2.3) 1.19 (0.36-3.47) .5 1.19 (0.33-3.22) 0.89 (0.74-3.47) .5
LY-DO indicates lymphocyte dose infused.cell dose infused. There was no significant difference
in lymphocyte recovery (ALC-15, ALC-30, ALC-60,
ALC-100, ALC-180, and ALC-365) in patients who
received$3.95  106/kg CD341 stem cells compared
to patients who received\3.95  106/kg (P . .1).
Effect of posttransplant G-CSF on lymphocyte
recovery following ASCT. In our study, 47 patients
received G-CSF on d 11 following ASCT (n 5 47)
and 72 patients did not receive it. On univariate anal-
ysis posttransplant G-CSF did not influence lympho-
cyte recovery. Although there was trend of higher
ALC recovery in patients who did not receive G-
CSF on d 11 following ASCT (ALC-60, ALC-100,
ALC-180, and ALC-365), the difference between 2
groups was only statistically significant at 12 months
(Figure 5).
DISCUSSION
ASCT improves survival of patients with MM [1],
although most patients will develop progressive dis-
ease after a period of remission. There are limited
prognostic markers to predict OS and PFS following
ASCT. Porrata et al. [14] reported that ALC-15$500 cells/mL is associated with significant longer
OS (P\ .0001) and PFS (P\ .0003) in MM patients.
In our study patients with ALC-15 $0.5  109/L did
not have significantly higher OS and PFS compared
to patients with ALC-15\0.5  109/L. This could
be because of very few patients in our study (n 5 19,
15%) achieved ALC-15 $0.5  109/L compared to
50% of patients in the Porrata et al. [14] study.
In our study, ALC-30 was a significant and inde-
pendent prognostic indicator of OS and PFS. Patients
with ALC-30 $1.0  109/L had higher OS and PFS
compared to patients with ALC-30 \1.0  109/L
(OS: P 5 .04; PFS: P 5 .028). Similarly, Kim et al.
[17] also reported that ALC recovery $1000 cells/
mm3 on day 23 following ASCT was an independent
predictor of OS and PFS inmyeloma patients. Oliveira
et al. [19] reported ALC-30 .500 cells/mL was an in-
dependent predictor of disease control following
ASCT. In our study ALC-30 $0.5  109/L was asso-
ciated with improved OS and PFS; however, we found
ALC-30 $1.0  109/L was a better discriminator of
OS and PFS. Higher lymphocyte recovery has been as-
sociated with prolonged survival in other hematologic
malignancies [6,8,9,14] and solid [7,20] tumors. AFigure 4. ALC following ASCT according to LY-DO: significantly higher ALC-60 (P5 .003) and ALC-100 (P5 .010) in
patients who received higher LY-DO.
122 D. K. Hiwase et al.potential explanation for survival advantage associated
with ALC recovery after ASCT is that early immune
reconstitution may have a protective effect against re-
sidual disease progression [14]. This is analogous to
theGVT effect in allogeneic SCT recipient, where do-
nor immune system is responsible for the eradication
of residual disease in the patient.
Another issue is the influence of lymphocyte recov-
ery kinetics on survival following ASCT. To address
this issue we have compared survival benefit of higher
lymphocyte recovery ($1.0  109/L) at different time
points following ASCT. We demonstrated a survival
benefit with higher ALC-30; however, this benefit
was not seen with higher ALC-60, ALC-100, ALC-
180, and ALC-365. Yoong et al. [21] reported signifi-
cantly longer OS and PFS in patients achieving ALC
$500 cells/mL by day 15 compared to patients with
ALC $500 cells/mL on days 16 to 20, days 21 to 25,
and days$26 (OS: P\ .0001 and PFS: P\ .0001) fol-
lowing ASCT in patients with NHL, MM, and AML
breast cancer. Our results, and those of others, suggest
that quicker and higher lymphocyte recovery within 30
days following ASCT improves survival. Patients who
slowly recover their lymphocyte count may not achieve
a similar benefit. Lack of survival benefit of delayed (af-
ter 30 days following ASCT) higher ALC may be ex-
plained by the concept of ‘‘tumor burden threshold’’
effect. There are definitive animal models showing
that the dose of inoculated tumor cells affects the abil-
ity of the immune system to eradicate the tumor [22].
Similar clinical observations regarding the timing of
immune recovery and the issue of tumor burden hav-
ing an impact on clinical outcome has been reported
after nonmyeloablative hematopoietic stem cell trans-
plantation (HSCT) [23]. It may be reasonable to
hypothesize that the delayed ALC recovery may allow
minimal residual disease to outgrow the rate of im-
mune reconstitution, thereby overcoming the benefits
of an autologous GVT effect.
We and others [10,14,17] have demonstrated that
higher lymphocyte recovery following ASCT is associ-
Figure 5. Effect of posttransplant (D11) G-CSF on lymphocyte re-
covery following ASCT.ated with better OS and PFS. This leads to the next
logical question: what determines lymphocyte recov-
ery following ASCT? There are 4 factors that may
be involved in the ALC recovery: CD34 stem cells,
reinfused graft lymphocytes, host stem cells, and host
lymphocytes surviving conditioning chemotherapy
[24].We and others [24] could not find any correlation
between the CD341 stem cells dose and ALC recovery.
Porrata et al. [24] have shown that patients who
received lymphocyte dose $0.5  109/kg achieved
higher ALC-15 compared to patients who received
lymphocyte dose\0.5  109/L (P 5 .0001). In our
study, LY-DO significantly influenced ALC recovery
in univariate analysis but not in multivariate analysis.
This could be because LY-DO is correlated with lym-
phocyte count on the day of leukapheresis (r2 5 0.53
and P\ .001), and hence, although LY-DO has bio-
logical influence, it failed to demonstrate its effect on
multivariate analysis. We have demonstrated that
there was continuous dose-dependent effect of LY-
DO infused on ALC recovery following ASCT. We
also observed that patients who died of progressive dis-
ease received a lower LY-DO compared with patients
who were alive at last follow-up. Porrata et al. [14]
demonstrated that patients who received lymphocyte
dose $0.5  109/kg had better OS and a longer time
to progression; however, we could not demonstrate
such a direct survival benefit. This could be explained
by lower median LY-DO infused in our study com-
pared to the Porrata et al. study (median LY-DO:
0.09  109/kg versus 0.5  109/kg), and there could
be an LY-DO threshold above which survival benefit
can be demonstrated directly.
Thus, our data and that of others [24,25] may sug-
gest that higher lymphocyte dose infused during
ASCT is associated with higher lymphocyte recovery
following ASCT. Is it only LY-DO that is important
or is the quality of lymphocytes also important? In
our study chemotherapy such as PCAB and melphalan
prior to stem cell collection adversely influenced lym-
phocyte recovery following ASCT. This may suggest
that alkylating agents could be damaging lymphocyte
progenitors leading to slower lymphocyte recovery
following ASCT.
Administration of G-CSF following SCT impairs
functional immune recovery in recipients of T cell-de-
pleted haploidentical SCT [26]. However, in non-T
cell-depletedHLAmatched allogeneic SCTposttrans-
plant G-CSF did not alter immunologic reconstitution
[27]. In our study, 47 patients received G-CSF on D
11. Lymphocyte recovery in these patients were not
significantly lower (for most of the time point except at
12months) compared to patientswhodid not receive it.
A limitation of our study, because of its retrospec-
tive nature, was the inability to delineate which lym-
phocyte subsets were involved in ALC recovery and
their relation to clinical outcome. We and others are
Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery 123currently working on analyzing the various subsets of
lymphocytes infused in autograft and subsets of lym-
phocytes recovered. A group from the Mayo Clinic
has reported that patients achieving an absolute natu-
ral killer (NK) cell count $80 cells/mL on day 15 had
significantly higher PFS compared to those who did
not. Similar analyses evaluating absolute CD3, CD4,
CD8, and CD19 counts were not significant [11].
In summary, our data suggest that infusing large
numbers of lymphocytes improves lymphocyte recov-
ery post-ASCT, and that higher ALC-30 is associated
with better PFS and OS. These data suggest that
a threshold number of CD341 cells should not be
the only parameter considered for an adequate PBSC
collection; perhaps a certain number of lymphocytes
should be aimed for as well.
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